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The mechanisms involved in the pathogenesis of ovarian cancer are poorly understood, but evidence suggests that aberrant activation
of Wnt/b-catenin signalling pathway plays a significant role in this malignancy. However, the molecular defects that contribute to the
activation of this pathway have not been elucidated. Frequently rearranged in advanced T-cell lymphomas-1 (FRAT1) is a candidate
for the regulation of cytoplasmic b-catenin. In this study, we developed in situ hybridisation probes to evaluate the presence of FRAT1
and used an anti-b-catenin antibody to evaluate by immunohistochemistry the expression levels and subcellular localisation of
b-catenin in ovarian cancer tissue microarrays. Expression of FRAT1 was found in some human normal tissues and 47% of ovarian
adenocarcinomas. A total of 46% of ovarian serous adenocarcinomas were positive for FRAT1 expression. Accumulation of b-catenin
in the nucleus and/or cytoplasm was observed in 55% ovarian adenocarcinomas and in 59% of serous adenocarcinomas. A significant
association was observed in ovarian serous adenocarcinomas between FRAT1 and b-catenin expression (Po0.01). These findings
support that Wnt/b-catenin signalling may be aberrantly activated through FRAT1 overexpression in ovarian serous adenocarcinomas.
The mechanism behind the overexpression of FRAT1 in ovarian serous adenocarcinomas and its significance is yet to be investigated.
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Ovarian cancer is the sixth most common cancer in women
worldwide and a highly aggressive gynaecological malignancy
producing almost 125 000 deaths yearly (Parkin et al, 2005).
Despite advances in detection and cytotoxic therapies, only 30% of
patients with advanced-stage ovarian cancer survive 5 years after
initial diagnosis (Parkin et al, 2005). Therefore, an understanding
of the molecular mechanisms involved in ovarian cancer
pathogenesis and progression has the potential to have a
significant impact on the outcomes for this devastating disease.
Most ovarian neoplasms are adenocarcinomas that occur as four
major histological subtypes, serous, mucinous, endometrioid and
clear cell, with serous being the most common. Current data
indicate that each of these histological subtypes is associated with
distinct morphologic and molecular genetic alterations (Bell,
2005). Further investigations of the molecular mechanisms
promoting ovarian cancer are necessary to determine how each
of the subtypes emerge. Relatively little is known about the
molecular events that lead to the development of ovarian cancer.
Recently, accumulation of nuclear and/or cytoplasmic b-catenin
has been observed in ovarian cancer (Gamallo et al, 1999; Wright
et al, 1999; Rask et al, 2003; Kildal et al, 2005). b-Catenin is a
multifunctional protein involved in at least two important
biological processes: cell–cell adhesion and Wnt/b-catenin signal-
ling pathway (Nelson and Nusse, 2004). It is believed that
accumulation of b-catenin in the cytoplasm favours its transloca-
tion to the nucleus as a cofactor for transcription factors of the
T-cell factor/lymphoid enhancing factor (TCF/LEF) family and
activates the transcription of Wnt/b-catenin target genes, which
are involved in cellular differentiation and proliferation (Giles
et al, 2003). Although compelling evidence has indicated a critical
role for signalling by b-catenin in the tumorigenesis of ovarian
cancer, mutations in the b-catenin gene are infrequent in ovarian
carcinoma and interestingly only described in the endometrioid
type of epithelial ovarian tumours (Gamallo et al, 1999; Wright
et al, 1999; Ueda et al, 2001; Giles et al, 2003). Mutations of
adenomatous polyposis coli (APC) or Axin occur rarely in ovarian
cancer (Giles et al, 2003). Therefore, additional mechanisms can
be used to upregulate b-catenin levels in other types of ovarian
tumours. Previous studies have shown that frequently rearranged
in advanced T-cell lymphomas-1 (FRAT1) is strikingly over-
expressed in some human cancer cells (Saitoh and Katoh, 2001;
Saitoh et al, 2002). Furthermore, FRAT1 is a positive regulator of
the Wnt/b-catenin pathway, which can inhibit glycogen synthase
kinase 3 (GSK-3) activity towards b-catenin, at least in part, by
preventing Axin binding to GSK-3 (Ferkey and Kimelman, 2002;
Fraser et al, 2002; Giles et al, 2003; van Amerongen and Berns,
2005). However, whereas FRAT1 is a candidate for the regulation
of cytoplasmic b-catenin, little is known with regard to the
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molecular relationship between FRAT1 and b-catenin in ovarian
cancer.
In this study, we developed in situ hybridisation probes to
evaluate the presence of FRAT1 and used an anti-b-catenin
antibody to evaluate by immunohistochemistry the expression
levels and subcellular localisation of b-catenin in formalin-fixed,
paraffin-embedded human normal tissues and ovarian tumour
tissues. This study was also aided by the use of tissue microarrays,
allowing a much larger cohort of patient samples to be evaluated
in a more standardised and rapid fashion. We demonstrate here
that FRAT1 is expressed in some human normal tissues and
overexpressed in human ovarian cancer. There is an obvious
correlation between FRAT1 overexpression and aberrant nuclear
and/or cytoplasmic accumulation of b-catenin in serous adeno-
carcinoma of ovary. Wnt/b-catenin signalling may be aberrantly
activated through FRAT1 overexpression in ovarian serous
adenocarcinomas.
MATERIALS AND METHODS
Construction of tissue arrays
TARP5-T-BO-1 tumour tissue arrays were constructed by the NCI
TARP Lab using anonymous donor blocks obtained from the
Cooperative Human Tissue Network. Detailed information about
TARP5-T-BO-1 tumour tissue arrays is available at www.cancer.
gov/tarp. The arrays were produced as described previously
(Hewitt, 2004), using a manual tissue arrayer (Beecher Instru-
ments, Silver Spring). The array design included specimens of 75
ovarian malignancies of surface epithelial origin, 65 breast
carcinomas and 35 cores of normal tissues representing 17
different histologies. Sections (5mm) were cut from the array blocks
using tape sectioning materials from Instrumedics (Hackensack,
NJ, USA).
Plasmids construction
The FRAT1 expression vector was constructed by cloning the open
reading frame of the human FRAT1 cDNA obtained from HEK293
cells into pcDNA3 vector (Invitrogen, CA, USA). Correct cloning of
FRAT1 cDNA fragments was confirmed by sequencing. The
resulting plasmid was designated FRAT1/pcDNA3. Probes for in
situ hybridisation were generated by in vitro transcription using
SP6 polymerase (Roche, Germany) as described below.
In situ hybridisation
For in situ hybridisation, digoxigenine (DIG)-labelled FRAT1
probes were prepared using a DIG-RNA-labelling kit (Roche),
according to the manufacturer’s instructions. In brief, FRAT1/
pcDNA3 plasmids were linearised with HindIII and DIG-labelled
probes were generated by in vitro transcription using SP6
polymerase (Roche). The amount of transcripts was monitored
by 2% agarose gel electrophoresis and determined by spectro-
photometry. Labelling efficiency was controlled by dot blot
analysis of serial probe dilutions.
In situ hybridisation was performed according to the method
described previously (Zhou et al, 2005). In brief, tissue sections
were deparaffinised, rehydrated in serial dilutions of ethanol, and
postfixed in 4% Tris-buffered saline (TBS)-buffered paraformal-
dehyde. Samples were treated with 0.2 mol l1 HCl for 10 min at
room temperature and then permeabilised using proteinase K
(100 mg l1) at 371C for 15 min. Digestion was stopped by washing
the samples in phosphate-buffered saline (PBS) (pH 7.4). The
samples were then dehydrated in serial dilutions of ethanol. DIG-
labelled FRAT1 probes were diluted in hybridisation buffer (50%
formamide, 4 SSC, 5% dextran sulphate, 5Denhardt’s solution
and 200 mg ml1 denatured salmon sperm DNA). After probes
were applied, the samples were covered with sterile coverslips.
Hybridisation was performed overnight at 421C in a sealed
humidified chamber containing 50% formamide. Nonspecific
binding or unbound probes were removed by the following
posthybridisation washes: 2 SSC at room temperature
(2 10 min), 1 SSC at room temperature (2 10 min), and
finally, the sections were washed in TBS containing 0.1% Tween-
20 (TTBS). Hybridisation signals were detected using an alkaline
phosphatase (AP)-conjugated anti-DIG antibody (Roche). After
washing in TTBS, the slides were incubated with nitro blue
tetrazolium/5-bromo-4-chloroindol-3-yl phosphate (NBT/BCIP)
(Roche) for 10 min. The FRAT1-positive cells were purple –blue
stained. The negative controls were incubated with hybridising
solution without FRAT1 probes.
Immunohistochemistry
Immunohistochemistry was performed using an UltraSensitivet
Kit (Maixin-Bio) according to the manufacturer’s protocol as
described previously (Wang et al, 2005). In brief, tissue sections
were deparaffinised, and rehydrated in serial dilutions of ethanol.
Endogenous peroxidase activity was blocked with 10-min incuba-
tion in a 3% hydrogen peroxide in PBS. Antigen retrieval was
performed by boiling in citrate buffer (0.01 M, pH¼ 6.0) in a
microwave oven. To reduce background nonspecific staining,
slides were incubated with normal nonimmune serum for 30 min.
The excess serum was removed and slides were incubated for
60 min with anti-b-catenin (C19220; 1 : 50; Transduction Lab, KY,
USA). Each incubation step was carried out at room temperature
and was followed by three sequential washes (5 min each) in PBS.
Slides were then incubated with biotin-conjugated second anti-
body for 30 min, followed by incubation with streptavidin –
peroxidase for 30 min. Peroxidase activity was identified by
applying 3,30-diaminobenzidine tetrachloride (DAB). Sections were
rinsed in water and counterstained with haematoxylin. Finally,
slides were dehydrated in alcohol, cleared in xylene. Slides were
also stained in the absence of primary antibody to evaluate
nonspecific secondary antibody reactions.
Evaluation of staining
All in situ hybridisation and immunostaining experiments were
assessed by two experienced pathologists who were blinded to
the origin of the sections. The membranous, cytoplasmic and
nuclear staining was determined separately for each specimen. The
staining intensity was graded as follows: 0, no staining; 1, weak
staining; 2, moderate staining and 3, intense staining. Owing to too
few cells or core missing in some sample cores, only 60 ovarian
samples out of 75 cores and 12 different normal tissue samples
in this tissue microarray were interpretable. For specimens that
were uninterpretable, a score of NA was given. The data from
breast samples are not shown here. In each case, the staining was
scored as an average throughout the spot. FRAT1 expression
within the tumour tissue was evaluated and categorised according
to the staining intensity. Tumours were then further grouped into
low (score 0) and high (scores 1– 3) expression of FRAT1.
Meanwhile, b-catenin protein expression profiles in cancer tissues
were further grouped into cytoplasm/nucleus accumulation or no
accumulation.
Statistical analysis
SPSS for Windows (SPSS Inc.) was used for statistical analysis.
Correlation between the FRAT1 expression levels and b-catenin
expression profiles on a per case basis was further analysed by
Spearman’s r correlation coefficient test. Values of Po0.05 were
considered statistically significant.
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RESULTS
Site of reaction products
The product of in situ hybridisation with the probes directed at
FRAT1 was located in the cytoplasm of the cells (Figure 1A).
Meanwhile, b-catenin immunostaining demonstrated two distinct
staining patterns: one that was predominantly cytoplasmic,
sometimes with concomitant nuclear staining and reduced
membranous staining (Figure 1C); and one that was with no
cytoplasmic or nuclear staining, often with membranous staining
(Figure 1D).
Expression of FRAT1 in human normal tissues
The tissue microarrays containing various normal tissues and
tumour tissues were hybridised with human DIG-labelled FRAT1
probes. The probes span the C-terminal coding region, minimising
the potential for crossreactivity between human FRAT1 and
FRAT2. Analysis of the tissue microarrays revealed that FRAT1
was expressed in human endometrium, testis, pancreas and
prostate (Figure 2). Expression of FRAT1 in other human normal
tissues, including cerebellum, colon, kidney, liver, lung, salivary,
spleen and thyroid, was not detected (Figure 2). These results were
consistent with a previous report (Freemantle et al, 2002).
Expression of FRAT1 and b-catenin in human ovarian
tumour tissues
FRAT1 was found in 28 of 60 (46%) ovarian adenocarcinomas
investigated. In total, 46% (19 out of 41) of all ovarian serous
adenocarcinomas were positive for FRAT1 expression, followed by
four out of 11 clear cell, four out of five endometrioid and one out
of three mucinous adenocarcinomas (Table 1). All analysed
ovarian tumours showed membrane b-catenin expression with
variable extension and intensity. Accumulation of b-catenin in the
nucleus and/or cytoplasm was observed in 33 of 60 (55%) ovarian
adenocarcinomas. In serous adenocarcinomas, the percentage of
cases with b-catenin accumulation was approximately 59%.
Nuclear and/or cytoplasmic expression of b-catenin was also
observed in four out of 11 clear cell, five out of five endometrioid
and zero out of three mucinous adenocarcinomas (Table 1).
Correlation between subcellular localisation of b-catenin
and overexpression of FRAT1 in ovarian serous
adenocarcinomas
To examine whether FRAT1 expression is correlated with
increased expression and cytoplasmic/nuclear localisation of
b-catenin in primary ovarian serous adenocarcinoma tissues, we
compare the expression of FRAT1 and the subcellular localisation
of b-catenin in 41 primary human ovarian serous adenocarcinoma
tissues by in situ hybridisation and immunohistochemical stain-
ing, respectively. Previous studies demonstrated that b-catenin has
an aberrant expression pattern in ovarian serous adenocarcinomas
(Rask et al, 2003; Kildal et al, 2005). Approximately 59% (24 out of
41) of ovarian serous adenocarcinoma samples showed cytoplas-
mic/nuclear accumulation accompanied by reduction of b-catenin
localisation at membranes. More importantly, in most cases,
b-catenin accumulation was correlated with high levels of FRAT1
expression in tumour specimens, whereas tumour tissues showing
no accumulation of b-catenin generally contained relatively low
levels of FRAT1 (Figure 1; Table 2). In 41 ovarian serous
adenocarcinoma tissues examined, there was a significant correla-
tion between FRAT1 and b-catenin expression, as determined by
the Spearman rank correlation test (Po0.01). These results suggest
that FRAT1 may modulate the Wnt/b-catenin pathway in ovarian
serous adenocarcinomas.
DISCUSSION
Ovarian cancer is one of the most complex malignancies with
a diversity of histological subtypes, including serous, clear cell,
mucinous and endometrioid (Bell, 2005). Limited information is
available as for the molecular alterations in ovarian cancer. The
reports about the expression of b-catenin in ovarian cancer are a
little confusing. However, it is consistent that nuclear b-catenin is
almost exclusively present in endometriod type of ovarian cancer
(Gamallo et al, 1999; Wright et al, 1999; Kildal et al, 2005). In other
types of ovarian cancer, including serous type, the predominant
aberrant expression pattern of b-catenin was cytoplasmic staining
without nuclear accumulation (Rask et al, 2003; Kildal et al, 2005).
These confusing phenomena may indicate and also may be due to
distinct molecular genetic alterations in different types of ovarian
caner (Bell, 2005). Although accumulation of cytoplasmic and
nuclear b-catenin has been observed in serous ovarian cancer
(Rask et al, 2003; Kildal et al, 2005), mutations of b-catenin in this
subtype occur rarely (Gamallo et al, 1999; Wright et al, 1999; Ueda
et al, 2001; Giles et al, 2003). The mechanism of accumulation of b-
catenin in ovarian serous adenocarcinomas might be independent
of genetic alterations of the b-catenin as shown in other tumours
(Giles et al, 2003). Further mechanisms to stabilise b-catenin
protein seem to be hidden in this subtype of ovarian cancer. It has
been suggested that downregulated expression of APC (Karbova
et al, 2002) or secreted frizzled-related proteins (SFRPs) inactiva-
tion by methylation (Takada et al, 2004) could explain, at least
partially, why ovarian serous adenocarcinomas show increased
b-catenin protein expression in spite of the absence of gene
mutation. However, none of these studies has shown any statistical
correlation between these molecules and subcellular localisation of
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Figure 1 Correlation between FRAT1 overexpression and b-catenin
localisation in human serous adenocarcinomas of ovary. Tissue microarrays
of paraffin-embedded ovarian adenocarcinomas were stained with in situ
hybridisation probes against FRAT1 or anti-b-catenin antibody and visualised
by NBT/BCIP or DAB staining, respectively. Left panels, a representative
high-FRAT1 staining specimen (A) with accumulation of b-catenin in the
cytoplasm and nucleus (C); right panels, a representative specimen with
low-FRAT1 staining (B) with no accumulation of b-catenin (D). Figures are
 100, and inserts are  400.
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b-catenin in tissue samples (Karbova et al, 2002; Takada et al,
2004). Whether deregulation of these molecules contributes to the
accumulation of b-catenin in ovarian serous adenocarcinomas is
yet to be established.
FRAT1 gene, mapping to human chromosome 10q24.1, is a
human homologue of mouse proto-oncogene Frat1 (Jonkers et al,
1997; Saitoh and Katoh, 2001). Frat1 was initially cloned in a
screen to identify genes that can accelerate lymphomagenesis in
Cerebellum Colon Kidney Liver
Lung Salivary Spleen Thyroid
Endometrium Testis Pancreas Prostate
Figure 2 Expression of FRAT1 in human normal tissues. The tissue microarrays containing various normal tissues were hybridised with human DIG-
labelled FRAT1 probes. Expression of FRAT1 was not detected in human cerebellum, colon, kidney, liver, lung, salivary, spleen and thyroid; meanwhile, there
was FRAT1 expression in human endometrium, testis, pancreas and prostate.
Table 1 Association of FRAT1 and b-catenin expression with histological type in ovarian adenocarcinoma
FRAT1, n (%) b-catenin, n (%)
Histological type No. High level Low level Accumulation No accumulation
Serous 41 19 (46) 22 (54) 24 (59) 17 (41)
Clear cell 11 4 (36) 7 (64) 4 (36) 7 (64)
Endometrioid 5 4 (80) 1 (20) 5 (100) 0 (0)
Mucinous 3 1 (33) 2 (67) 0 (0) 3 (100)
Total 60 28 (47) 32 (53) 33 (55) 27 (45)
Table 2 Comparison of FRAT1 and b-catenin expression in serous adenocarcinoma of ovary
FRAT1 expression
b-Catenin staining Low level (n¼ 22) High level (n¼19) Total
Accumulation 7 (17%) 17 (41%) 24 (59%)
No accumulation 15 (37%) 2 (5%) 17 (41%)
Total 22 (54%) 19 (46%) 41 (100%)
The level of FRAT1 expression and localisation of b-catenin were determined in 41 surgical specimens of serous adenocarcinoma of ovary, as shown in Figure 1. The correlation
was analysed using a Spearman rank correlation test, Po0.01.
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Moloney murine leukaemia virus (M-MuLV)-infected Eı`-Pim1 or
H2-K-Myc transgenic mice (Jonkers et al, 1997). Its biological
function remained unknown until its Xenopus homologue GSK-3-
binding protein (GBP) was identified as a GSK-3-binding protein
(Yost et al, 1998). GSK-3-binding protein is required to specify the
dorsal– ventral axis in Xenopus embryos. It appears to inhibit the
GSK-3-mediated phosphorylation of b-catenin, stabilising it on the
future dorsal side of the embryo. Previous studies indicated that
FRAT1 is a component of the Wnt signalling pathway (Yost et al,
1998; Thomas et al, 1999). Overexpression of FRAT1 leads to
b-catenin stabilisation through dissociation of GSK-3b from Axin
and inhibition of b-catenin phosphorylation (Li et al, 1999;
Thomas et al, 1999). Unphosphorylated b-catenin is stabilised and
translocated to the nucleus to associate with TCF/LEF transcrip-
tion factors (Giles et al, 2003). The b-catenin/TCF complex
activates the transcription of Wnt target genes such as c-myc
(He et al, 1998), cyclin D1 (Tetsu and McCormick, 1999) and
human pituitary tumour transforming gene (hPTTG) (Zhou et al,
2005). These genes play an important role in the development and
formation of some neoplasias. Thus, FRAT1 is a positive regulator
of the Wnt/b-catenin pathway. Since the identification of human
FRAT1, an additional homologue has been discovered in the
human genome. FRAT2, just like FRAT1, functions as positive
regulator of the Wnt pathway. FRAT1 and FRAT2 are more
homologous in the N-terminal region, but are completely divergent
in the C-terminal region (Saitoh et al, 2001; Freemantle et al, 2002).
So our probes against human FRAT1 span the C-terminal coding
region of this gene, minimising the potential for crossreactivity
between human FRAT1 and FRAT2. Recently, results from van
Amerongen et al (2005) and van Amerongen and Berns (2005)
demonstrate that murine Frat is not an essential component of the
canonical Wnt pathway in mice. However, since that the regulatory
mechanisms about Wnt pathway are complex and still obscure,
there may be the presence of parallel pathways that are
functionally redundant and may compensate for the loss of Frat.
Furthermore, it is notable that some previous reports suggest that
Frat plays a role in tumour progression (Jonkers et al, 1997, 1999).
Therefore, it implies that in abnormal conditions, such as in the
FRAT-overexpressed cancer cells, FRAT may be an important
molecular event that might lead to the aberrant activation of Wnt
pathway.
In this study, we used in situ hybridisation probes to
demonstrate the presence of FRAT1 in paraffin-embedded human
normal tissues and ovarian cancer tissues. To our knowledge, no
other research group has been able to produce in situ hybridisa-
tion probes against FRAT1 to date. In situ hybridisation seems to
be a more selective and more specific technique than immuno-
histochemistry, but requires greater care in preparing nuclease-
free solutions. Tissue microarrays were also used for the rapid and
efficient analysis of large numbers of paraffin-embedded tissues
(Braunschweig et al, 2004, 2005). By using in situ hybridisation to
detect the expression of FRAT1 and by using immunohistochem-
istry to detect the expression of b-catenin on tissue microarrays of
paraffin-embedded ovarian adenocarcinomas, we report here that
cytoplasmic/nuclear accumulation of b-catenin is closely asso-
ciated with FRAT1 overexpression in ovarian serous adenocarci-
nomas. Although it is uncertain whether FRAT1 expression is the
cause or effect of cytoplasmicb-catenin in certain circumstances,
until now, almost all data shown in the literatures indicate that
FRAT1 is a positive regulator of the Wnt/b-catenin pathway.
No reports now suggest that Wnt/b-catenin pathway can regulate
the expression of FRAT1. Thus, a strong correlation between
expression of FRAT1 and the subcellular localisation of b-catenin
indicates that FRAT1 may modulate the Wnt/b-catenin pathway in
ovarian serous adenocarcinomas. A study with larger cohort seems
mandatory to clarify whether the same role of FRAT1 exists in
other histological subtypes of ovarian cancer, such as clear cell,
endometrioid and mucinous adenocarcinomas. In addition, we
report that FRAT1 is detected in some normal human tissues,
including endometrium, testis, pancreas and prostate. Similar
results have been obtained by other researchers (Freemantle et al,
2002). Unfortunately, normal human ovary tissues are not
included in this tissue microarray. However, data from Freemantle
et al (2002) demonstrated that human FRAT1 expression levels in
the ovary were relatively low but detectable. van Amerongen and
Berns (2005) suggest that murine Frat is expressed in rapidly
dividing cells (van Amerongen et al, 2005). Similar expression
pattern of human FRAT1 may also be observed, but it needs
further investigation.
In conclusion, FRAT1 mRNA and b-catenin protein expression
were studied in 60 ovarian adenocarcinomas, including 41 serous,
11 clear cell, five endometrioid and three mucinous adeno-
carcinomas. We report the expression pattern of FRAT1 in
some normal human tissues and that overexpression of
FRAT1 in ovarian serous adenocarcinomas is significantly
associated with cytoplasmic/nuclear accumulation of b-catenin.
Wnt/b-catenin signalling may be aberrantly activated through
FRAT1 overexpression in ovarian serous adenocarcinomas.
The mechanism behind the overexpression of FRAT1 in ovarian
serous adenocarcinomas and its significance is yet to be
investigated.
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